Go Pro
→ They're not buying gold. They're buying this. (From Behind the Markets) (Ad)tc pixel Free SRNE Stock Alerts

Sorrento Therapeutics (SRNE) Competitors

Sorrento Therapeutics logo
$0.0008 0.00 (0.00%)
As of 11:01 AM Eastern
Compare

SRNE vs. NMTR, EVFM, JAGX, HEPA, and CERO

Should you buy Sorrento Therapeutics stock or one of its competitors? Sorrento Therapeutics's main competitors and comparable companies include 9 Meters Biopharma (NMTR), Evofem Biosciences (EVFM), Jaguar Animal Health (JAGX), Hepion Pharmaceuticals (HEPA), and CERo Therapeutics (CERO). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Sorrento Therapeutics compare to 9 Meters Biopharma?

Sorrento Therapeutics (NASDAQ:SRNE) and 9 Meters Biopharma (NASDAQ:NMTR) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, dividends, earnings, profitability, media sentiment and risk.

Sorrento Therapeutics has a beta of 0.11, suggesting that its stock price is 89% less volatile than the broader market. Comparatively, 9 Meters Biopharma has a beta of 1.36, suggesting that its stock price is 36% more volatile than the broader market.

In the previous week, Sorrento Therapeutics' average media sentiment score of 0.00 equaled 9 Meters Biopharma'saverage media sentiment score.

Company Overall Sentiment
Sorrento Therapeutics Neutral
9 Meters Biopharma Neutral

0.0% of Sorrento Therapeutics shares are held by institutional investors. Comparatively, 22.3% of 9 Meters Biopharma shares are held by institutional investors. 2.6% of Sorrento Therapeutics shares are held by insiders. Comparatively, 2.4% of 9 Meters Biopharma shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Sorrento Therapeutics' return on equity of 0.00% beat 9 Meters Biopharma's return on equity.

Company Net Margins Return on Equity Return on Assets
Sorrento TherapeuticsN/A N/A N/A
9 Meters Biopharma N/A -584.97%-159.45%

9 Meters Biopharma has lower revenue, but higher earnings than Sorrento Therapeutics. Sorrento Therapeutics is trading at a lower price-to-earnings ratio than 9 Meters Biopharma, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Sorrento Therapeutics$60.32M0.01-$572.84M-$0.17N/A
9 Meters BiopharmaN/AN/A-$43.77M-$3.46N/A

Summary

Sorrento Therapeutics beats 9 Meters Biopharma on 5 of the 9 factors compared between the two stocks.

How does Sorrento Therapeutics compare to Evofem Biosciences?

Sorrento Therapeutics (NASDAQ:SRNE) and Evofem Biosciences (NASDAQ:EVFM) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, analyst recommendations, risk, earnings, media sentiment, institutional ownership, profitability and dividends.

Evofem Biosciences has lower revenue, but higher earnings than Sorrento Therapeutics. Evofem Biosciences is trading at a lower price-to-earnings ratio than Sorrento Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Sorrento Therapeutics$60.32M0.01-$572.84M-$0.17N/A
Evofem Biosciences$11.39M0.09$52.98M-$0.13N/A

Sorrento Therapeutics has a net margin of 0.00% compared to Evofem Biosciences' net margin of -46.42%. Sorrento Therapeutics' return on equity of 0.00% beat Evofem Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Sorrento TherapeuticsN/A N/A N/A
Evofem Biosciences -46.42%-91.97%-61.93%

Sorrento Therapeutics has a beta of 0.11, meaning that its share price is 89% less volatile than the broader market. Comparatively, Evofem Biosciences has a beta of -1.3, meaning that its share price is 230% less volatile than the broader market.

In the previous week, Evofem Biosciences had 1 more articles in the media than Sorrento Therapeutics. MarketBeat recorded 1 mentions for Evofem Biosciences and 0 mentions for Sorrento Therapeutics. Sorrento Therapeutics' average media sentiment score of 0.00 equaled Evofem Biosciences'average media sentiment score.

Company Overall Sentiment
Sorrento Therapeutics Neutral
Evofem Biosciences Neutral

0.0% of Sorrento Therapeutics shares are owned by institutional investors. Comparatively, 0.2% of Evofem Biosciences shares are owned by institutional investors. 2.6% of Sorrento Therapeutics shares are owned by insiders. Comparatively, 0.0% of Evofem Biosciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Sorrento Therapeutics beats Evofem Biosciences on 7 of the 12 factors compared between the two stocks.

How does Sorrento Therapeutics compare to Jaguar Animal Health?

Jaguar Animal Health (NASDAQ:JAGX) and Sorrento Therapeutics (NASDAQ:SRNE) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, media sentiment, analyst recommendations, institutional ownership, dividends, valuation and profitability.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Jaguar Animal Health
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Sorrento Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Jaguar Animal Health has higher earnings, but lower revenue than Sorrento Therapeutics. Sorrento Therapeutics is trading at a lower price-to-earnings ratio than Jaguar Animal Health, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Jaguar Animal Health$11.51M0.12-$53.43M-$3.73 thousandN/A
Sorrento Therapeutics$60.32M0.01-$572.84M-$0.17N/A

Jaguar Animal Health has a beta of -0.11, indicating that its stock price is 111% less volatile than the broader market. Comparatively, Sorrento Therapeutics has a beta of 0.11, indicating that its stock price is 89% less volatile than the broader market.

Sorrento Therapeutics has a net margin of 0.00% compared to Jaguar Animal Health's net margin of -187.88%.

Company Net Margins Return on Equity Return on Assets
Jaguar Animal Health-187.88% N/A -131.45%
Sorrento Therapeutics N/A N/A N/A

In the previous week, Jaguar Animal Health had 2 more articles in the media than Sorrento Therapeutics. MarketBeat recorded 2 mentions for Jaguar Animal Health and 0 mentions for Sorrento Therapeutics. Jaguar Animal Health's average media sentiment score of 0.13 beat Sorrento Therapeutics' score of 0.00 indicating that Jaguar Animal Health is being referred to more favorably in the media.

Company Overall Sentiment
Jaguar Animal Health Neutral
Sorrento Therapeutics Neutral

12.0% of Jaguar Animal Health shares are held by institutional investors. Comparatively, 0.0% of Sorrento Therapeutics shares are held by institutional investors. 0.2% of Jaguar Animal Health shares are held by company insiders. Comparatively, 2.6% of Sorrento Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

Jaguar Animal Health beats Sorrento Therapeutics on 7 of the 13 factors compared between the two stocks.

How does Sorrento Therapeutics compare to Hepion Pharmaceuticals?

Sorrento Therapeutics (NASDAQ:SRNE) and Hepion Pharmaceuticals (NASDAQ:HEPA) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, valuation, earnings, profitability, media sentiment, analyst recommendations, risk and institutional ownership.

Sorrento Therapeutics has a beta of 0.11, indicating that its stock price is 89% less volatile than the broader market. Comparatively, Hepion Pharmaceuticals has a beta of 1.52, indicating that its stock price is 52% more volatile than the broader market.

0.0% of Sorrento Therapeutics shares are held by institutional investors. Comparatively, 17.2% of Hepion Pharmaceuticals shares are held by institutional investors. 2.6% of Sorrento Therapeutics shares are held by insiders. Comparatively, 0.1% of Hepion Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, Hepion Pharmaceuticals had 1 more articles in the media than Sorrento Therapeutics. MarketBeat recorded 1 mentions for Hepion Pharmaceuticals and 0 mentions for Sorrento Therapeutics. Sorrento Therapeutics' average media sentiment score of 0.00 equaled Hepion Pharmaceuticals'average media sentiment score.

Company Overall Sentiment
Sorrento Therapeutics Neutral
Hepion Pharmaceuticals Neutral

Hepion Pharmaceuticals has lower revenue, but higher earnings than Sorrento Therapeutics. Sorrento Therapeutics is trading at a lower price-to-earnings ratio than Hepion Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Sorrento Therapeutics$60.32M0.01-$572.84M-$0.17N/A
Hepion PharmaceuticalsN/AN/A-$48.93M-$72.15N/A

Sorrento Therapeutics' return on equity of 0.00% beat Hepion Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Sorrento TherapeuticsN/A N/A N/A
Hepion Pharmaceuticals N/A -812.56%-207.31%

Summary

Sorrento Therapeutics beats Hepion Pharmaceuticals on 6 of the 10 factors compared between the two stocks.

How does Sorrento Therapeutics compare to CERo Therapeutics?

CERo Therapeutics (NASDAQ:CERO) and Sorrento Therapeutics (NASDAQ:SRNE) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, risk, dividends, media sentiment, profitability, valuation, earnings and institutional ownership.

29.6% of CERo Therapeutics shares are owned by institutional investors. Comparatively, 0.0% of Sorrento Therapeutics shares are owned by institutional investors. 0.4% of CERo Therapeutics shares are owned by insiders. Comparatively, 2.6% of Sorrento Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

CERo Therapeutics has a beta of 0.19, meaning that its share price is 81% less volatile than the broader market. Comparatively, Sorrento Therapeutics has a beta of 0.11, meaning that its share price is 89% less volatile than the broader market.

CERo Therapeutics has higher earnings, but lower revenue than Sorrento Therapeutics. Sorrento Therapeutics is trading at a lower price-to-earnings ratio than CERo Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
CERo TherapeuticsN/AN/A-$8.30M-$9.84N/A
Sorrento Therapeutics$60.32M0.01-$572.84M-$0.17N/A

CERo Therapeutics presently has a consensus price target of $30.00, suggesting a potential upside of 285,614.29%. Given CERo Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe CERo Therapeutics is more favorable than Sorrento Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
CERo Therapeutics
1 Sell rating(s)
2 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.67
Sorrento Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Company Net Margins Return on Equity Return on Assets
CERo TherapeuticsN/A N/A -209.40%
Sorrento Therapeutics N/A N/A N/A

In the previous week, CERo Therapeutics' average media sentiment score of 0.00 equaled Sorrento Therapeutics'average media sentiment score.

Company Overall Sentiment
CERo Therapeutics Neutral
Sorrento Therapeutics Neutral

Summary

CERo Therapeutics beats Sorrento Therapeutics on 6 of the 10 factors compared between the two stocks.

Get Sorrento Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for SRNE and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SRNE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

SRNE vs. The Competition

Export
MetricSorrento TherapeuticsPharmaceuticals IndustryHealthcare SectorNASDAQ Exchange
Market Cap$441K$12.26B$7.13B$13.27B
Dividend YieldN/A2.63%2.53%15.88%
P/E Ratio0.00797.17273.9926.15
Price / Sales0.01751.40608.6593.06
Price / CashN/A81.7977.3851.25
Price / BookN/A10.3810.886.34
Net Income-$572.84M$2.84B$3.50B$361.18M
7 Day PerformanceN/A-1.27%-1.62%-1.17%
1 Month PerformanceN/A-5.49%-5.90%-3.40%
1 Year PerformanceN/A-3.38%9.47%3.28%

Sorrento Therapeutics Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
SRNE
Sorrento Therapeutics
N/A$0.00
flat		N/A-77.1%$441K$60.32MN/A949
NMTR
9 Meters Biopharma
N/AN/AN/AN/A$1.04MN/AN/A20
EVFM
Evofem Biosciences
N/A$0.01
flat		N/A-44.8%$1.02M$11.39MN/A120
JAGX
Jaguar Animal Health
0.3099 of 5 stars		$34.46
+1,190.6%		N/A-99.7%$920K$11.51MN/A47
HEPA
Hepion Pharmaceuticals
N/A$0.08
-1.0%		N/A+117.4%$903KN/AN/A20

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:SRNE) was last updated on 10/2/2026 by MarketBeat.com Staff.
From Our Partners
This AI fund posted a 34 percent annualized payout last month
One small fund tied to artificial intelligence stocks delivered $1,051 in a single month, not through selling ...
Investors Alley | Sponsoredtc pixel
Elon Warns "America Will Go Bankrupt". Trump's Plan Inside.
National debt just crossed 40 trillion dollars, and Elon Musk says America is 1,000% going to go bankrupt with...
American Hartford Gold | Sponsoredtc pixel
Small Colorado Company (Backed by Sam Altman) Could Save U.S. Power Grid
A small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...
Altimetry | Sponsoredtc pixel
The SEC Just Opened The Floodgates…
The SEC removed the 25 year old Pattern Day Trader rule in June 2026, cutting the minimum to open a trading ac...
StocksToTrade | Sponsoredtc pixel
The end of AI data centers coming?
Marc Chaikin's Power Gauge system flagged Micron before it soared 970 percent, Celestica before a 6,600 percen...
Chaikin Analytics | Sponsoredtc pixel
Major Buy Alert Issued for October 31st
Keith Kaplan has invested $17 million into his own AI research tools, building a platform now used by 180,000 ...
TradeSmith | Sponsoredtc pixel
How options let you do more with less capital
Would you rather spend $5,000 buying 100 shares of a $50 stock, or control those same 100 shares for a fractio...
Base Camp Trading | Sponsoredtc pixel
The "velvet rope" stock setups hiding from regular indicators
K.I.R.A. is a new trading engine built to flag market setups before they show up on standard charts. Former...
The TradingPub | Sponsoredtc pixel